Targeted Drug Delivery and Penetration Into Solid Tumors

被引:93
作者
Corti, Angelo [1 ,2 ]
Pastorino, Fabio [3 ]
Curnis, Flavio [1 ,2 ]
Arap, Wadih [4 ]
Ponzoni, Mirco [3 ]
Pasqualini, Renata [4 ]
机构
[1] Ist Sci San Raffaele, Div Mol Oncol, I-20132 Milan, Italy
[2] Ist Sci San Raffaele, IIT Network Res Unit Mol Neurosci, I-20132 Milan, Italy
[3] G Gaslini Childrens Hosp, Lab Oncol, Expt Therapy Unit, Genoa, Italy
[4] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr, Houston, TX 77030 USA
关键词
chemotherapy; doxorubicin; liposomes; vascular targeting; NGR; NGR-hTNF; NGR-TNF; CD13; av ss 3 integrin; isoDGR; ISOLATED LIMB PERFUSION; NECROSIS-FACTOR-ALPHA; PEGYLATED-LIPOSOMAL DOXORUBICIN; SYNERGISTIC ANTITUMOR-ACTIVITY; NEOVASCULATURE-HOMING MOTIF; AMINOPEPTIDASE-N; INTERFERON-GAMMA; MOUSE MODEL; NGR-HTNF; CANCER;
D O I
10.1002/med.20238
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Delivery and penetration of chemotherapeutic drugs into tumors are limited by a number of factors related to abnormal vasculature and altered stroma composition in neoplastic tissues. Coupling of chemotherapeutic drugs with tumor vasculature-homing peptides or administration of drugs in combination with biological agents that affect the integrity of the endothelial lining of tumor vasculature is an appealing strategy to improve drug delivery to tumor cells. Promising approaches to achieve this goal are based on the use of Asn-Gly-Arg (NGR)-containing peptides as ligands for drug delivery and of NGR-TNF, a peptide-tumor necrosis factor-a fusion protein that selectively alters drug penetration barriers and that is currently tested in a randomized Phase III trial in patients with malignant pleural mesothelioma.
引用
收藏
页码:1078 / 1091
页数:14
相关论文
共 83 条
[1]  
Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121
[2]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[3]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[4]  
Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014
[5]   Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin [J].
Balza, E ;
Mortara, L ;
Sassi, F ;
Monteghirfo, S ;
Carnemolla, B ;
Castellani, P ;
Neri, D ;
Accolla, RS ;
Zardi, L ;
Borsi, L .
CLINICAL CANCER RESEARCH, 2006, 12 (08) :2575-2582
[6]   Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer [J].
Bellone, Matteo ;
Mondino, Anna ;
Corti, Angelo .
TRENDS IN IMMUNOLOGY, 2008, 29 (05) :235-241
[7]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[8]   Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience [J].
Bieker, Ralf ;
Kessler, Torsten ;
Schwoeppe, Christian ;
Padro, Teresa ;
Persigehl, Thorsten ;
Bremer, Christoph ;
Dreischalueck, Johannes ;
Kolkmeyer, Astrid ;
Heindel, Walter ;
Mesters, Rolf M. ;
Berdel, Wolfgang E. .
BLOOD, 2009, 113 (20) :5019-5027
[9]   Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: Preclinical studies [J].
Brunstein, F ;
Hoving, S ;
Seynhaeve, ALB ;
van Tiel, ST ;
Guetens, G ;
de Bruijn, EA ;
Eggermont, AMM ;
ten Hagen, TLM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (21) :1603-1610
[10]   cNGR: A novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo [J].
Buehler, Alexandra ;
van Zandvoort, Marc A. M. J. ;
Stelt, Bram J. ;
Hackeng, Tilman M. ;
Schrans-Stassen, Bianca H. G. J. ;
Bennaghmouch, Abdelkader ;
Hofstra, Leo ;
Cleutjens, Jack P. M. ;
Duijvestijn, Adriaan ;
Smeets, Mirjam B. ;
de Kleijn, Dominique P. V. ;
Post, Mark J. ;
de Muinck, Ebo D. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (12) :2681-2687